Outcomes Study of Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ Treated with Excision

被引：0
|
作者：
Qian, J. [1 ]
Rizki, A. [1 ]
Chong, J. [1 ]
Richey, J. [1 ]
Ticar, J. [1 ]
Shan, L. [1 ]
Idowu, M. [1 ]
机构：
[1] Virginia Commonwealth Univ, Richmond, VA USA
来源：
MODERN PATHOLOGY | 2012年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
240
引用
收藏
页码：60A / 60A
页数：1
相关论文
共 50 条
  • [31] Extent and Histologic Pattern of Atypical Ductal Hyperplasia Present on Core Needle Biopsy Specimens of the Breast Can Predict Ductal Carcinoma In Situ in Subsequent Excision
    Wagoner, Michael J.
    Laronga, Christine
    Acs, Geza
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 131 (01) : 112 - 121
  • [32] COMPARATIVE ULTRASTRUCTURE OF ATYPICAL DUCTAL HYPERPLASIA, INTRADUCTAL CARCINOMA, AND INFILTRATING DUCTAL CARCINOMA OF BREAST
    GOLDENBERG, VE
    GOLDENBERG, NS
    SOMMERS, SC
    CANCER, 1969, 24 (06) : 1152 - +
  • [33] Atypical Ductal Hyperplasia and Those Boarding on Ductal Carcinoma in Situ Should be Included in the Active Surveillance Clinical Trials
    Khoury, Thaer
    Jabbour, Nashwan
    Peng, Xuan
    Yan, Li
    Quinn, Marie
    MODERN PATHOLOGY, 2019, 32
  • [34] Atypical Ductal Hyperplasia and Those Bordering on Ductal Carcinoma In Situ Should Be Included in the Active Surveillance Clinical Trials
    Khoury, Thaer
    Jabbour, Nashwan
    Peng, Xuan
    Yan, Li
    Quinn, Marie
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 153 (01) : 131 - 138
  • [35] Atypical Ductal Hyperplasia and Those Boarding on Ductal Carcinoma in Situ Should be Included in the Active Surveillance Clinical Trials
    Khoury, Thaer
    Jabbour, Nashwan
    Peng, Xuan
    Yan, Li
    Quinn, Marie
    LABORATORY INVESTIGATION, 2019, 99
  • [36] Chemoprevention uptake among women with atypical hyperplasia, lobular and ductal carcinoma in situ
    Coe, A. M.
    Trivedi, M. S.
    Vanegas, A.
    Kukafka, R.
    Crew, K. D.
    CANCER RESEARCH, 2017, 77
  • [37] Cyclin D1 expression in usual hyperplasia, atypical ductal hyperplasia and low nuclear grade ductal carcinoma in situ of the breast: an immunohistochemical study
    Monaghan, H
    Scott, D
    Schrimankar, J
    Bell, H
    Marsh, A
    McIntosh, GG
    Angus, B
    JOURNAL OF PATHOLOGY, 1999, 187 : 25A - 25A
  • [38] Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ
    Trivedi, Meghna S.
    Coe, Austin M.
    Vanegas, Alejandro
    Kukafka, Rita
    Crew, Katherine D.
    CANCER PREVENTION RESEARCH, 2017, 10 (08) : 434 - 441
  • [39] Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ
    Martinez, Anthony P.
    Cohen, Cynthia
    Hanley, Krisztina Z.
    Li, Xiaoxian
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (07) : 686 - 689
  • [40] The Utilities of Estrogen Receptor, Cytokeratin 5/6, and Cytokeratin 903 to Differentiate Between Usual Ductal Hyperplasia, Flat Epithelial Atypia, Atypical Ductal Hyperplasia, Ductal Carcinoma In Situ, and Lobular Carcinoma In Situ
    Wei, Eric
    Dela Cruz, Nestor
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2018, 149 : S30 - S30
12345